Oct. 29, 2015:

Be aware during National Breast Cancer Awareness Month, and you will see more than pink ribbons. Woven through the many emerging stories of inspiration, you’ll see strong, supportive, empowering relationships: teams.

Member institutions of the Big Ten Cancer Research Consortium know something about teaming up to fight breast cancer. Through their unique collaboration, these game-changing leaders are modeling what is possible when competitors on the field become partners in the fight against cancer. Read More

Oct. 16, 2015:

Breakthroughs and breakaways: these are the exciting results of the Big Ten Cancer Centers’ collective fight against cancer. In this month’s edition of Across the Consortium, we recount the innovative breakthroughs of member institutions asking – and answering – big questions in oncology. Non-drug treatments, cutting-edge device development, and genetic analyses are just a few highlights. We also glean inspiration from the breakaway performances of Big Ten research leaders achieving new milestones and paving the way for the leaders of tomorrow. As the impact of senior faculty deepens, new training programs broaden the pool of future talent.

Read More

Oct. 1, 2015:

A conversation with Timothy L. Ratliff, PhD, Robert Wallace Miller Director of the Purdue University Center for Cancer Research, which is a member of the Big Ten Cancer Research Consortium.

Q: How do you think cancer research will change in the next 10 or 20 years?

There will be a much greater focus on individual care, i.e., personalized medicine. I am hopeful that the FDA will make changes that embody the personalized approach. There is likely to be significant advances in immunotherapy and control of epigenetic gene regulation. Read More

Oct. 1, 2015:

From a contracts perspective, what does a Big Ten institution need to do to open as a site in a Big Ten Cancer Research Consortium (Big Ten CRC) study?

Each Big Ten CRC institution signed a master site agreement, called an Institutional Participant Agreement (the “IPA”), when it joined the Big Ten CRC. If an institution wants to participate as a site in a particular study, Big Ten CRC Administrative Headquarters (AHQ) will provide a study-specific work order under the IPA. The work order will include a site budget and any study-specific terms required by the study funder or sponsor investigator’s institution (e.g., study-specific intellectual property terms). Read More

Sept. 18, 2015:

Member institutions of the Big Ten Cancer Research Consortium consistently lay the foundations for ground-breaking cancer research – in more ways than one! Across the consortium, members are breaking ground for a new research facility and advancing research through new approaches, new business ventures, and new discoveries. This month, we highlight innovation, recognize the receipt of prestigious grants, and celebrate the “ground breaking” being done – Across the Consortium!

Read More

Aug. 31, 2015:

The Big Ten Cancer Research Consortium Foundation is accepting donations to support the collaborative research activities of the Big Ten Cancer Research Consortium (Big Ten CRC).

Big Ten CRC member institutions support the work of 2,600 cancer researchers, provide care for more than 50,000 new cancer patients every year, and enroll 20,000 patient volunteers to participate in cancer clinical trials. Donations to the Foundation support a wide range of activities that help the Big Ten CRC further its mission to transform the conduct of cancer research through collaborative, hypothesis-driven, highly translational oncology trials that leverage the scientific and clinical expertise of Big Ten universities.

Donations may be given online at https://bigtencrc.org/donate-now/ or mailed (payable to Big Ten Cancer Research Consortium Foundation, Inc.) to: Read More

Aug. 31, 2015:

A conversation with Howard Bailey, MD, director of the UW Carbone Cancer Center, which is a member of the Big Ten Cancer Research Consortium (Big Ten CRC):

Q: How do you think cancer research will change in the next 10-20 years?

The increased collection of clinical information will lead to increased numbers of specific, potential directions to pursue unlike in the past when any new direction was embraced and pursued. The future of cancer research will involve much more “virtual research” or informatics confirmation prior to pursing a direction clinically and the need to work together to identify cancer patients with shared “personalized cancer data” for innovative targeted or personalized treatments. Read More

Aug. 25, 2015:

Ultimate success in the fight against cancer requires advances at every stage. In this month’s edition of Across the Consortium, we celebrate victories at a number of critical stages in cancer research. Through thesis formation to diverse funding acquisition, opportunities for new programs arise, leading to further innovation, collaboration, and success.

Read More

Aug. 17, 2015:

What type of trial is the Big Ten Cancer Research Consortium (Big Ten CRC) looking to perform?

The Big Ten CRC’s mission is to perform novel, hypothesis-driven, highly translational oncology trials. Two other important components in Big Ten CRC trials is mentorship between junior and senior investigators as well as cross-collaboration between Big Ten CRC institutions. See the complete list of Big Ten CRC Research Criteria. Read More

July 16, 2015:

As the Big Ten Cancer Research Consortium (Big Ten CRC) faces off against complex, diverse cancers, our member institutions continue to leverage their unique strengths to volley game-changing breakthroughs. This month’s edition of Across the Consortium highlights recent advancements on the fields of research, funding, diagnosis, and treatment.

Read More